Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lertxundi, U.
Right arrow Articles by García-Moncó, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lertxundi, U.
Right arrow Articles by García-Moncó, J. C.
American Journal of Health-System Pharmacy, Vol. 65, Issue 5, 414-419
Copyright © 2008. American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/04/0602-1242$06.00


Clinical Consultation

Antidopaminergic therapy for managing comorbidities in patients with Parkinson’s disease

Unax Lertxundi, Javier Peral, Oihana Mora, Saioa Domingo-Echaburu, María Jose Martínez-Bengoechea and Juan Carlos García-Moncó

UNAX LERTXUNDI, PHARM.D., is Hospital Pharmacist; JAVIER PERAL, PHARM.D., is Hospital Pharmacist; OIHANA MORA, PHARM.D., is Hospital Pharmacist; SAIOA DOMINGO-ECHABURU, PHARM.D., is Hospital Pharmacist; and MARIA JOSE MARTINEZ-BENGOECHEA, PHARM.D., is Hospital Pharmacist, Pharmacy Service, Hospital de Galdakao- Usansolo, Galdakao, Spain. JUAN CARLOS GARCIA-MONCO, M.D., is Neurologist, Neurology Service, Hospital de Galdakao-Usánsolo.

Address correspondence to Dr. Unax Lertxundi at the Servicio de Farmacia, Hospital de Galdakao-Usánsolo, Barrio Labeaga s/n, 48960 Galdakao, Vizcaya, Spain (ulertxundi{at}hotmail.com).


Purpose. A literature evaluation of antidopaminergic therapies in patients with Parkinson’s disease (PD) who have developed psychosis, nausea, vomiting, and hiccups was conducted.

Summary. Complications associated with the use of antiparkinsonian drugs make PD management more difficult given the need for antidopaminergic therapy, which worsens motor functioning in patients with PD. For psychosis, clozapine is the only atypical antipsychotic that has proven effective without worsening motor function in PD patients. However, its use requires the monitoring of agranulocytosis. Newer atypical antipsychotics such as quetiapine have been claimed to be safe in terms of motor functioning, but evidence about their effectiveness is not compelling. The emergency treatment of psychosis in PD would require parenteral administration, only available for olanzapine and ziprasidone. However, no randomized controlled trials have been conducted to establish the efficacy and safety in this setting. For nausea and vomiting, very little domperidone crosses the blood–brain barrier. As a result, the risk of developing extrapyramidal adverse effects is minimal. Metoclopramide blocks central dopamine receptors and worsens motor parkinsonian symptoms. Chlorpromazine, the first-line treatment of intractable hiccups, is contraindicated in PD. Baclofen could be considered as a first-line alternative.

Conclusion. Although clozapine can be used to treat psychosis in patients with PD, managing nausea, vomiting, hiccups, and emergent psychotic symptoms in these patients remains a challenge due to a lack of evidence for currently available options.

Index terms: Antiemetics; Antiparkinson agents; Antipsychotic agents; Dopamine antagonists; Hiccup; Nausea; Parkinson disease; Psychotic disorders; Toxicity; Vomiting

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society of Health-System Pharmacists.